These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26078468)

  • 1. Cross-over-it's a feature, not a bug.
    Engelsberg A
    Ann Oncol; 2015 Sep; 26(9):2000-2002. PubMed ID: 26078468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.
    Pennell NA
    Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP84-7. PubMed ID: 22693986
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in the battle against lung tumour resistance.
    Furlow B
    Lancet Respir Med; 2014 May; 2(5):353. PubMed ID: 24963524
    [No Abstract]   [Full Text] [Related]  

  • 4. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L; Zhang H; Shao W; Chen B
    Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

  • 10. Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.
    Tucker ER; Danielson LS; Innocenti P; Chesler L
    Cancer Res; 2015 Jul; 75(14):2770-4. PubMed ID: 26122839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract]   [Full Text] [Related]  

  • 13. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib.
    Riess JW; Nagpal S; Neal JW; Wakelee HA
    J Natl Compr Canc Netw; 2013 Apr; 11(4):389-94. PubMed ID: 23584342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
    Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
    J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Straughan DM; Azoury SC; Shukla V
    Curr Drug Targets; 2016; 17(6):739-45. PubMed ID: 26073862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
    Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial watch: success for crizotinib in ALK-driven cancer.
    Nat Rev Drug Discov; 2010 Dec; 9(12):908. PubMed ID: 21119722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.